Flucrypyrim, a novel uterine relaxant, has antinociceptive and anti-inflammatory effects \textit{in vivo}

Zhongtang Li$^{1,2,*}$, Limei Wang$^{1,*}$, Yue Cong$^{1,*}$, Lin Guo$^{1}$, Xiaohui Lin$^{1}$, Zuyin Yu$^{1}$, Xingan Wu$^{3}$, Junxing Dong$^{4}$, Rifang Yang$^{2}$ & Yuwen Cong$^{1}$

Consequences of primary dysmenorrhea (PD) can be severe. Increased prostaglandin production leads to uterine contraction and insufficient blood flow to the endometrium causing ischemia and pain symptoms. Protein tyrosine kinase/phosphatase activities contribute to the modulation of uterine contraction. In our previous study, we found the synthetic (α-methoxyacrylates) compound Fluacrypyrim (FAPM), significantly increased protein tyrosine phosphatases (PTPs) activity, resulting in dephosphorylation of tyrosine kinases. In the present study, we found that FAPM near completely inhibited prostaglandin F$_2\alpha$ (PGF$_{2\alpha}$)-, oxytocin-, acetylcholine-, and high K$^+$-induced uterine contractions in rats \textit{in vitro}, and decreased rat myometrial myosin light chain (MLC$_{20}$) phosphorylation induced by PGF$_{2\alpha}$. A structure–activity relationship assay indicated that the α-methoxyacrylates structure of FAPM is crucial for the inhibition of PGF$_{2\alpha}$-induced uterine contractions. FAPM caused a concentration-dependent parallel rightward shift of the concentration–response curve induced by oxytocin, dose-dependently reduced the number of abdominal constrictions and increased the latency time in PGF$_{2\alpha}$- and acetic acid-induced writhing test in mice \textit{in vivo}. Furthermore, FAPM considerably inhibited the development of Carr-induced rat paw edemas and thexylene-induced mouse ear edemas. Taken together, our results indicate that FAPM exerts antinociceptive and anti-inflammatory effects \textit{in vivo} with considerable potential as a novel uterine relaxant.

Primary dysmenorrhea (PD), or painful menses, is considered one of the most common gynecological complaints among adolescent and young adult women\(^1\). It is characterized by menstrual cramps and lower abdominal pain and may be associated with nausea, vomiting, diarrhea, headache, dizziness, and/or back pain. The prevalence of PD is highest among adolescent women, affecting from 20 to 90 of this age group\(^2\). Moreover, ~15% percent of adolescent girls suffer from such severe dysmenorrhea, that this condition represents the leading cause of school and work absenteeism\(^3\). Notably, the cause of PD still remains unclear\(^4\).

It is believed that prostaglandin (PG) release plays an important role in the pathogenesis of dysmenorrhea. PGF$_{2\alpha}$, a cyclooxygenase (COX) metabolite of arachidonic acid, have also been shown to have important implications to this disease\(^5\). Notably, the cause of PD still remains unclear\(^4\).

Recently, studies have shown that protein tyrosine kinase/phosphatase activities control both phosphorylation and activation of signaling proteins including: phospholipase C-γ, Ca$^{2+}$-dependent tyrosine kinase Pyk2, c-Src and Lck kinases. Together these signaling pathways modulate uterine contractions induced by contractile agonists such as PGF$_{2\alpha}$\(^12-14\). More specifically, the tyrosine kinase inhibitor genistein, by example, released uterine

---

$^1$Department of Pathophysiology, Beijing Institute of Radiation Medicine, Beijing, China. $^2$Department of Medicinal Chemistry, Beijing Institute of Pharmacology and Toxicology, Beijing, China. $^3$Department of Microbiology, Fourth Military Medical University, 17 Changle Xi Road, Xi’an, Shaanxi Province, 710032, PR China. $^4$Department of Pharmaceutical Sciences, Beijing Institute of Radiation Medicine, Beijing, China. $^*$These authors contributed equally to this work. Correspondence and requests for materials should be addressed to Y.C. (email: congyw@nic.bmi.ac.cn)
contractions elicited by pervanadate, a protein tyrosine phosphatase inhibitor, which can potentiate contractile receptor-mediated contraction\textsuperscript{15,16}. Similarly, Imatinib mesylate suppresses the contractile activity of human uterus by inhibiting the tyrosine kinase activity of c-kit, PDGFR, and abl\textsuperscript{17,18}. Tyrosine phosphorylation results from the dynamic equilibrium between phosphorylation and dephosphorylation reactions, the latter of which is regulated through the activity of protein tyrosine phosphatases (PTPs)\textsuperscript{19}. In our previous work, we found fluacrypyrim (FAPM), identified as a potent STAT3 activation inhibitor, significantly increases PTPs activity in a dose-dependent manner. Furthermore, FAPM-induced suppression of STAT3 tyrosine phosphorylation can be reversed via sodium pervanadate, which highlights the importance of FAPM in regulating PTPs\textsuperscript{20}. In the study described herein, we examined the direct effects of FAPM on uterine contraction in a rat model and evaluated the analgesic and anti-inflammatory effects \textit{in vivo}. Moreover, we report a novel, inhibitory role of FAPM on rat uterine contractions induced by stimulators and evaluate the analgesic and anti-inflammatory activities of this agent \textit{in vivo}.

**Results**

**Effects of FAPM and its analogs on PGF$_{2\alpha}$-induced uterine contractions in the rats.** To investigate the \textit{in vivo} inhibition of PGF$_{2\alpha}$-induced uterine contraction by FAPM, we first examined the effect of FAPM on PGF$_{2\alpha}$-induced uterine contraction \textit{in vitro}. As shown in Fig. 1b, application of nanomolar concentration of PGF2α (450 nM final concentration in the bath solution) produced phasic contractions of constant amplitude and frequency. FAPM exerted a relaxant effect on PGF$_{2\alpha}$-induced uterine contraction in a concentration-dependent manner (0.625–10 μmol/L). A representative recording of the inhibition of both frequency and amplitude of contractions induced by FAPM is shown in Fig. 1c. The contractions expressed as percentage of the response to 450 nM PGF$_{2\alpha}$ were measured as the AUC at 10-min intervals to characterize the inhibitory activity of FAPM. On the basis of the dose–response curve (Fig. 1b), FAPM induced a complete (100%) reduction in contractility.
IFAPM was 7.72 of the dose–response curve (Fig. 1c), the net maximum reduction in contractility for HTFAPM, FAPMA and (IFAPM), the inhibitory activity of IFAPM was significant (P < 0.001), but lower than that of FAPM. On the basis of the dose–response curve (Fig. 4c), the percentage of net maximum reduction in contractility for HTFAPM, FAPMA and IFAPM was 7.72 ± 3.52%, 6.84 ± 3.11% and 42.15 ± 4.49% respectively. The structure–activity relationship assay indicated that both methyl group (C19) at O18-position and isopropyl group at O14-site in FAPM are critical for the effect, while the bonding site of arylmethyl group to the pyrimidine is also critical.

Effects of FAPM on oxytocin-induced uterine contractions in rats. Oxytocin is a nonapeptide hormone that stimulates uterine and mammary gland contractions via oxytocin receptor. To determine whether FAPM exerted an inhibitory effect on oxytocin-induced contractions, different doses of FAPM were administered along with oxytocin (1 mU/ml). As showed in Fig. 1b, removing the isopropyl group from the Schild plot analysis were 1.78 ± 0.03, 6.84 ± 3.11% and 42.15 ± 4.49% respectively. The structure–activity relationship assay indicated that both methyl group (C19) at O18-position and isopropyl group at O14-site in FAPM are critical for the effect, while the bonding site of arylmethyl group to the pyrimidine is also critical.

In vitro analysis of the effects of FAPM on acetylcholine and KCl-induced uterine contractions. Acetylcholine (Ach) behaves as an excitatory neurotransmitter at neuromuscular junctions in uterine smooth muscle. As shown in Fig. 4a, application of 0.25 μM Ach produced phasic contractions of constant amplitude and frequency, and administration of FAPM along with Ach exerted an inhibitory effect on uterine contractile force (amplitude) and frequency. Based on the dose–response curve (Fig. 4b), the percentage of net maximum reduction in contractility for FAPM was 100% vs. 13.81 ± 2.68% for Vehicle (P < 0.001), with the average pD2 value of 5.79.

Effects of FAPM on PGF2α-induced MLC20 phosphorylation. Phosphorylation of MLC20 primarily regulated by calcium- and calmodulin-dependent myosin light chain kinase (MLCK) is a key regulator of smooth muscle contraction. To study whether FAPM inhibits MLC20 phosphorylation, rat myometrial cells was treated with FAPM (2.5, 5, and 10 μM) along with PGF2α (10⁻⁶ M). As shown in Fig. 5, the application of PGF2α for 5 min induced MLC20 phosphorylation, and FAPM treatment (5 and 10 μM) significantly reduced the PGF2α-induced MLC20 phosphorylation in a dose-dependent manner.
Analgesic activity of FAPM on the acetic acid-induced writhing test. The writhing test was used to evaluate the analgesic activity of FAPM. Administration of FAPM (50, 100 and 200 mg/kg) 1 h before acid injection produced a significant and dose-dependent inhibition of acetic acid-induced abdominal constrictions in mice (Fig. 6a). The latency time was also found to be increased significantly in a dose dependent manner in the FAPM group (Fig. 6b). FAPM (100 mg/kg) demonstrated a significant inhibition of acetic acid-induced writhing response, similar to that of indomethacin (50 mg/kg), a standard NSAID used as positive control. The FAPM group (200 mg/kg) exhibited the maximum inhibiting effect of acetic acid-induced writhing and the longest latency time (12.2 min) - almost six fold long as that in the vehicle control group (2.2 min).
Anti-inflammatory activities of FAPM in mouse and rat swelling models. Prostaglandin release is thought to be a pathogenic factor associated with PD. Therefore, the anti-inflammatory activities of FAPM were evaluated using the mouse ear swelling model. As shown in Fig. 7a, treatment of mice with FAPM (100 mg/kg) significantly inhibited the xylene-induced ear edema by 43.76% (p < 0.001). Treatment with indomethacin (10 mg/kg) also reduced the ear edema for 17.95% (p > 0.05).

As expected, the volume of the injected hind paw of rats was increased by subplantar injection of carrageenan (edema), which peaked 3 h post-injection. The time course for the development of paw edema following administration of FAPM (100 mg/kg, i.p.) is shown in Fig. 7b. Dexamethasone (4 mg/kg, i.g.), a steroid used to treat many inflammatory and autoimmune conditions, was used as a positive control. Two agents were able to significantly reduce the paw edema at 2 and 3 h post-injection. The inhibition of paw swelling by FAPM and dexamethasone was 42.12% (p < 0.01) and 64.05% (p < 0.001) respectively (Fig. 7c).

Effect of FAPM on a mouse model of PD. PGF$_{2\alpha}$ plays an important role in the pathogenesis of PD. PGF$_{2\alpha}$-induced writhing response occurred within 30 min after injection of PGF$_{2\alpha}$ in the females pretreated with estrogen while male mice did not experience any reactions. Administration of FAPM (100 and 200 mg/kg), 1 hour prior to PGF$_{2\alpha}$ injection, highlighted a significant and dose-dependent inhibition of PGF$_{2\alpha}$-induced abdominal constrictions in mice (Fig. 8a). Indomethacin, the positive control, showed a significant inhibition of
PGF$_{2\alpha}$-induced writhing response, similar to that of FAPM (100 mg/kg). The FAPM group (200 mg/kg) exhibited the maximum inhibiting effect of PGF$_{2\alpha}$-induced writhing (Fig. 8a) and a significantly increased latency time ($p < 0.01$) (Fig. 8b).

**Figure 7.** FAPM reduces inflammatory activities on mouse and rat swelling models. (a) Effects of FAPM on xylene-induced ear edema were shown. Animals were pretreated by FAMP (100 mg/kg), Indomethacin (10 mg/kg) or vehicle 60 min before the test ($n = 10$). (b) Effects-time curves of FAPM on Carr-induced paw edema. (c) Effects of FAPM on Carr-induced paw edema. Animals were pretreated by FAMP (100 mg/kg), Dexamethasone (4 mg/kg) or vehicle for 3 consecutive days ($n = 6$). The values represent the mean ± S.E.M.; *$p < 0.05$; **$p < 0.01$; ***$p < 0.001$ vs. control (vehicle) group. Inhibition percentage of the edema is expressed at the top in the bar.

**Figure 8.** FAPM reduces PGF$_{2\alpha}$-induced pain response. (a) The number of writhes was counted for 30 min after PGF$_{2\alpha}$ administration. (b) The time to onset of writhing was recorded after PGF$_{2\alpha}$ administration. Results were expressed as means ± S.E.M ($n = 10$). **$p < 0.01$ vs. control (vehicle) group.
Discussion
Protein tyrosine kinase/phosphatase activities contribute to the modulation of uterine contractions induced by contractile agonists or stretch via tyrosine phosphorylation and dephosphorylation reactions. We previously reported that fluacrypyrim (FAPM) significantly increases the protein tyrosine phosphatases (PTPs) activity in a dose-dependent manner, inhibiting protein tyrosine phosphorylation which can be reversed by PTP inhibitor sodium pervanadate. In the present study, we firstly demonstrated that FAPM treatment near completely inhibited PGF$_2\alpha$, oxytocin-, Ach-, and high K$^+$-induced uterine contractions in rats in vitro, with similar pD2 value from 5.72 to 5.92.

Uterine contraction is realized by the phosphorylation of 20kDa myosin light chain (MLC$_{20}$) at Ser19, stimulating the ATPase activity of the smooth muscle myosin. The levels of MLC$_{20}$ are regulated by opposing activities of MLCK (mitogen-activated protein kinase) and MLC phosphatase (MLCP). To stimulate MLCK by contractile agonists, such as PGF$_2\alpha$, oxytocin, et al., are mainly dependent upon increasing cytosolic Ca$^{2+}$ and inhibiting MLCP. As expected, we found FAPM, a novel inducer of PTPs, significantly reduced the PGF$_2\alpha$-induced MLC$_{20}$ phosphorylation in a dose-dependent manner, which indicated that FAPM inhibited smooth muscle contraction by affecting MLCK activity.

It has been reported that activated phospholipase C-γ1 (PLC-γ1), produced in response to tyrosine phosphorylation, appears to be an important factor in uterine contractions, and Lck and c-Src kinases act an important role in regulating tyrosine phosphorylation of PLC-γ1 and uterine contractions in rats. The sustained smooth muscle contraction induced by vascular smooth muscle cell membrane depolarization involves genistein-sensitive tyrosine phosphorylation, leading to phosphorylation of MYPT1 (the myosin-targeting subunit of MLCP) and MLC$_{20}$. The Ca$^{2+}$–dependent tyrosine kinase Pyk2 (proline-rich tyrosine kinase 2) was then identified as the major tyrosine-phosphorylated protein in response to membrane depolarization. Tyrosine kinase inhibitors, such as genistein, PP1, PP2, among others, attenuated uterine contractions elicited by the stimulation of contractile receptors, whereas the protein tyrosine phosphatase inhibitors, such as pervanadate, bpV(phen), et al., potentiated receptor-mediated contraction. Hear we found FAPM, a novel inducer of PTPs, caused a concentration-dependent parallel rightward shift in the oxytocin-induced concentration–response curve without any reduction in maximal contractile response, demonstrating a competitive antagonism by FAPM against the oxytocin-induced contraction. These data indicated that inhibition of FAPM on myometrial MLC$_{20}$ phosphorylation and contraction induced by contractile agents may be mediated through the increase of the PTPs activity.

Reversible oxidation of PTPs has emerged as an important regulatory mechanism whereby reactive oxygen species (ROS) inactivates PTPs, promotes phosphorylation and induction of the signaling cascade. Mitochondrial reactive oxygen species (ROS), a major source of ROS in eukaryotic cells, are generally involved in oxidative stress, whereby complex III derived ROS especially has been involved in cellular redox signaling pathways. However, a detailed understanding of the molecular mechanisms that trigger the generation of signaling ROS from mitochondrial cytochrome bc1 complex is missing. FAPM, with a β-methoxyacrylates structure, is proposed to be an inhibitor of mitochondrial cytochrome bc1 complex. A structure–activity relationship assay indicated that the β-methoxyacrylates structure, a pharmacophore of class Ia inhibitors of mitochondrial cytochrome bc1 complex, is crucial for the inhibition of PGF$_2\alpha$-induced uterine contraction. At present, we do not know whether the effects of FAPM on uterine contraction are directly related to the inhibition of mitochondrial cytochrome bc1 complex. The biochemical mechanism by which FAPM operates is still needed and should be evaluated in future studies.

Clinical studies have demonstrated high PGF$_2\alpha$ levels are associated with dysmenorrhea. Moreover, prostanoid's signaling has been shown to directly affect uterine contraction, and therefore may represent the most significant contributor to PD. In China, the PGF$_2\alpha$ or oxytocin-induced writhing mouse models, represent frequently-used pain models of PD. We established this model and evaluated the anti-dysmenorrhea effects of FAPM. We noted that intraperitoneal administration of FAPM reduced the number of abdominal constrictions in a dose-dependent manner and increased the latency time when assessed in PGF$_2\alpha$-induced writhing in mice in vivo. These results indicate that FAPM may be potentially useful in the release of PD.

Inflammation is also believed to be involved in the pathogenesis of PD. A previous study reported that non-steroidal anti-inflammatory drugs could be utilized in the treatment of PD. Several studies have evaluated the effect of a cyclooxygenase-2 (COX-2) inhibitor as a treatment for PD. Our study evaluated the anti-inflammatory effects of FAPM, using classical xylene-induced ear-edema model. As a chemical agent, xylene can cause severe vasodilation and edematous changes of skin partially associated with phospholipase A$_2$ (PLA$_2$) activity. Our results indicate that FAPM significantly inhibited xylene-induced ear edema. This effect may be produced by inhibiting the release of PLA$_2$, thereby reducing the concentrations of prostanooids and leukotrienes. For the further evaluation of the anti-inflammatory effects of FAPM, we performed a carrageenan-induced paw-edema assay in rats, which induces the development of edema in three phases: the early phase (the first 90 min) involving the release of histamine and serotonin; the second phase (90–150 min) mediated by kinin and the third phase (after 180 min) mediated by prostaglandin. As shown in our results, FAPM significantly inhibited the development of the edemas induced by Carr after 2 h of treatment, while dexamethasone, a steroid anti-inflammatory agent as a positive control, inhibited the development of edema 1–3h after treatment. Together these results further suggest that the anti-inflammatory mechanism of FAPM may be related to the inhibition of prostanooids and leukotrienes production.

The acetic acid-induced writhing test, an assay widely employed to assess anti-inflammatory and analgesic activities, is considered to be a model for visceral inflammatory pain. It is generally thought that acetic acid lead to stimulation of nociceptive neurons by increasing endogenous mediators, such as prostaglandin and histamine, in peritoneal fluids. We found FAPM reduced the abdominal constrictions in a dose-dependent manner and increased the latency time when assessed in acetic acid-induced writhing in
mice. These results suggest the effect of FAPM could be attributed, at least in part, to a reduction of inflammatory mediators.

Above all, we found FAPM, a novel inducer of PTPs, significantly reduced the PGF$_{2\alpha}$-induced MLC$_{20}$ phosphorylation, near completely inhibited PGF$_{2\alpha}$-, oxytocin-, Ach-, and high K$^+$-induced uterine contractions in rats in vitro, and caused a concentration-dependent parallel rightward shift in the oxytocin-induced concentration–response curve. In consistent with the in vitro activity, we demonstrated FAPM dose-dependently reduced the number of abdominal constrictions and increased the latency time in PGF$_{2\alpha}$-, and acetic acid-induced writhing test in mice in vivo. It was then found that FAPM inhibited the development of Carr-induced rat paw edemas and thexylene-induced mouse ear edemas. A structure–activity relationship assay based on the inhibition of PGF$_{2\alpha}$-induced uterine contraction indicated that the mitochondrial cytochrome bc1 complex may be the target of FAPM for its uterine relaxant effect as well as its antinociceptive and anti-inflammatory activity, through the inhibition of ROS production from mitochondria. Therefore, rational modifications of FAPM by medicinal chemistry techniques are anticipated to obtain derivative uterine relaxants with better specificity and therapeutic potential for patients suffering from PD.

Materials and Methods

Materials. PGF$_{2\alpha}$, Oxytocin, acetylcholine (Ach), indomethacin, Xylene, Carrageenan and dexamethasone were purchased from Sigma (St. Louis, MO). Actin antibody, phospho-myosin light chain-20 (p-MLC$_{20}$, ser19) antibody and HRP goat anti-rabbit IgG were obtained from Cell Signaling Technology (Beverly, MA). Fluacrypyrim (FAPM) and its analogs were synthesized by Dr. Yang's lab. Stock solutions were prepared in DMSO. Estrostilben was obtained from Beijing Yimen Co. Ltd and dissolved in 0.9% sodium chloride.

Ethics Statement. This study was approved by Beijing Experimental Animal Ethics Committee (2006) No. 5118 set by the Beijing People's Government.

Animals. SPF KM male and female mice, weighting from 22 to 28 g, and female Sprague Dawley (SD) rats, weighing 120–140 g were purchased from the Laboratory Animal Center, Chinese Academy of Medical Sciences. The animals were kept in an environmentally controlled room at 22 ± 2°C with free access to pellet food and water on a 12-h light/dark cycle. All animal procedures were performed in accordance with the National Institutes of Health guidelines for the care and use of laboratory animals. The method of euthanasia was cervical dislocation and the method of anesthesia which we used in some tests was intraperitoneal administration of sodium pentobarbital.

Assessment of Uterine Contractility in vitro. Female SD rats were administered intraperitoneally with estradiol benzoate (0.1 mg/kg) for 2 days before the experiments. Rats were sacrificed by cervical dislocation. Uteri were removed and then cut into 10 × 2 × 2 mm$^3$ strips along the longitudinal axis. The uterine strips mounted vertically in an organ bath containing 5 ml organ baths of Krebs’ solution (136 mM NaCl, 2.68 mM KCl, 1.8 mM CaCl$_2$, 0.5 mM MgCl$_2$, 11.9 mM NaHCO$_3$, 0.32 mM NaH$_2$PO$_4$ and 5.04 mM glucose, pH 7.2), aerated continuously with 95% O$_2$/5% CO$_2$, and maintained at 37 ± 0.2°C. The tension of the myometrial rings was measured isometrically with a tension transducer connected to a polygraph system (Beijing Microsignalstar Technology Development Co., Ltd, China). To ensure contractile viability and to determine maximum contraction, the solution for each strip was first changed to 40 mM K$^+$ for 10 min. The strips which did not respond to KC1 were discarded. The recorded value to 40 mM K$^+$ for 10 min was taken as the control. Each uterine strip was allowed to equilibrate at 1 g tension for 20 min until a steady tension was achieved and then treated with different agents (PGF$_{2\alpha}$, oxytocin, Ach, or KC1) to stimulate uterine contraction. Various concentrations of FAPM were then added to the bath solution in a cumulative manner at 10-min intervals. Mechanical responses of uterine strips were analyzed by the area under the curve (AUC) according to the response curve of each uterine strip tested and expressed as a percentage of the control.

Antagonism assay for oxytocin-induced contraction. As described above, uterine strips were prepared and disposed before the experiment. Each uterine strip was allowed to equilibrate at 1 g tension for 20 min until a steady state and then treated with vehicle and FAPM of 0.25 μM, 0.5 μM and 1 μM. Various concentrations of oxytocin were then added to the bath solution in a cumulative manner at 10-min intervals. Mechanical responses of uterine strips were analyzed by the area under the curve (AUC) according to the response curve of each uterine strip tested and expressed as a percentage of the control. EC$_{50}$ of oxytocin for each group was calculated and the Schild regression analysis was performed using the following formula:

$$\log (d_r - 1) = \log [M] - \log K_M$$

$$\log (d_r - 1) = \log \frac{FAPM}{FAPM/vehicle} - \log \frac{vehicle}{vehicle}; M = 0.25 \times 10^{-6}, 0.5 \times 10^{-6} \text{ or } 1 \times 10^{-6}$$

And pA$_2$ = logK$_M$ when log(dr – 1) = 0 in the linear plot.

Culture of Dispersed Myometrial Cells. Primary cultures of uterine smooth muscle cells were prepared as previously described by us$^{25}$. Briefly, uteri was removed from estrostilben primed rats and dissected free of fat and endometrium. The tissues were cut into 1 × 1 × 1 mm$^3$ pieces and placed in culture flasks containing DMEM medium supplemented with 15% fetal bovine serum (FBS) and maintained at 37°C in 5% CO$_2$ atmosphere. Cells were subcultured every 3–4 days prior to reaching confluence. When most of the cells had contracted and become rounded, the semi-dispersed cells were washed with PBS twice, and trypsin (0.25% w/v) was added. FBS was added to neutralize the effect. The dissociated myometrial cells were collected by centrifugation (200 g for 15 min)
and resuspended in DMEM medium containing 10% FBS, then plated on glass coverslips for 24 h at 37 °C in 5% CO₂ atmosphere before the experiments.

**Total Protein Extraction.** Protein extraction was performed according to the method as previously described by us. Briefly, myometrial cells were plated at a cell density of 5 × 10⁴ cells/well in 60-mm culture plates and cultured in serum-free DMEM for 24 h. After treatment with varying concentrations of FAPM and PGF₂α, for 5 min, myometrial cells were washed with cold PBS three times, and then 2 × SDS loading buffer was added. The cell lysates were then boiled for 10 min and pelleted by centrifugation (10,000 g, 5 min). The samples were aliquoted and stored at −20 °C for further use.

**MLC₂₀ Phosphorylation Analysis.** MLC₂₀ phosphorylation was analyzed by Western blot as previously described. In brief, the cell lysates were centrifuged at 12,000 × g for 10 min at 4 °C. Equal amounts of protein (20 μg) were separated on 12% SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and then transferred to nitrocellulose membranes. The membranes were probed with the phospho-Ser-19-specific antibody, followed by an HRP-conjugated secondary antibody. The enhanced chemiluminescence system detection kit (Cell Signaling) was used to visualize the immunoreactive proteins on PVDF membranes.

**Acetic acid-induced abdominal writhing in mice.** Acetic acid-induced writhing test was performed according to the previously described methods with minor modification. Fifty mice were divided randomly into five groups. One hour before the test, a single dose of FAPM (50, 100 and 200 mg/kg) and indomethacin (50 mg/kg) were administered intraperitoneally. The mice were then injected intraperitoneally with acetic acid (0.6%, v/v in saline, 10 ml/kg b w., i.p.) and placed in separated boxes. The number of abdominal writhing was recorded for 30 min and the time that passed until the first appearance of writhing was recorded as the latency of pain response. For the precision and accuracy of the results, two well-trained lab technicians performed the test in a double-blind manner.

**Xylene-induced ear edema in mice.** The xylene-induced ear edema test was performed according to the previously described methods. In brief, fifty mice were divided randomly into five groups. 1 h before the test, a single dose of FAPM (50, 100 and 200 mg/kg) and indomethacin (50 mg/kg) were administered intraperitoneally. The xylene was applied to the inner and outer surface of the right ear, while the left ear kept untreated. One hour later, mice were sacrificed and the central sections of the right and left ears were obtained using a stainless steel 6 mm punch. The weight difference between the sections of the right and left ears was used to evaluate ear edema. The ear edema percent was calculated using the following equation:

$$\text{Ear edema percent} = \left( \frac{\text{Weight}_{\text{right}} - \text{Weight}_{\text{left}}}{\text{Weight}_{\text{right}}} \right) \times 100\%.$$  

**Carrageenan induced paw edema in rats.** Carrageenan induced paw edema in rats was conducted according to the method described previously, with minor modification. Eighty rats were divided randomly into three groups. Before edema induction, the test groups were orally administered with dexamethasone (4 mg/kg), intraperitoneally injected with FAPM (100 mg/kg) and vehicle (DMSO, 20%) for 3 consecutive days. 30 min after the last administration, the rat left hind paw was injected sub-plantar with 0.1 ml of 1% carrageenan to induce edema, while the right hind paw kept untreated. Paw thickness was measured with a digital micrometer at 0, 1, 2, and 3 hours following injection. The rats were sacrificed at 3 h after carrageenan injection. Both hind paws were removed from the knee joint and weighed with an analytical balance. An increase in paw weight (in g) between the treated and the untreated paw was used to evaluate the degree of the hind paw swelling and the inhibition percent of paw swelling was calculated by using the following equation:

$$\text{Percentage anti-inflammatory activity} = \left( \frac{C - T}{C} \right) \times 100\%$$  

where C and T indicate the non-treated and drug treated edema, respectively.

**In vivo mouse model of PD.** In brief, fifty female mice were randomly separated into five groups. Before the test, each mouse was intragastrically treated with 0.2 mg diethylstilbestrol daily for 12 days. On the twelfth day, 30 min after the last administration, the test groups were intraperitoneally injected with FAPM (50, 100 and 200 mg/kg), indomethacin (50 mg/kg) and vehicle (DMSO, 20%). 1 hour after drug administration, the mice were treated with PGF₂α (i.p. 1.3 mg/kg) and placed in separated boxes. The writhing responses were observed for 30 min and the time that passed until the first appearance of writhing was recorded as the latency of pain response. For the precision and accuracy of the results, two well-trained lab technicians performed the test in a double-blind manner.

**Statistical Analysis.** Results are expressed as means ± SEM for n samples, and statistical analyses were performed using the GraphPad Prism 5 software (GraphPad Software, San Diego, CA). Student’s t-test was used for comparison of the means of two groups. One-factor ANOVA followed by Dunnett’s test was applied for MLC₂₀ phosphorylation analysis (Fig. 5b), acetic acid-induced abdominal writhing assay (Fig. 6) and PGF₂α-induced pain response assay (Fig. 8). Two-factor ANOVA followed by Student-New-Keuls (SNK-q) test was applied for the inhibition experiment of uterine contraction (Figs 1c, 2b and 4b,c) and paw edema assay (Fig. 7b). Values of P < 0.05 were considered significant.
References

1. Harel, Z. Dysmenorrhea in adolescents. Am. NY Acad Sci 1135, 185–195 (2008).
2. Schroede, B. & Sanfilippo, J. S. Dysmenorrhea and pelvic pain in adolescents. Pediatr Clin North Am 46, 555–571 (1999).
3. Banikarim, C., Chacko, M. R. & Kelder, S. H. Prevalence and impact of dysmenorrhea on Hispanic female adolescents. Arch Pediatr Adolesc Med 154, 1226–1229 (2000).
4. Dawood, M. Y. Primary dysmenorrhea: advances in pathogenesis and management. Obstet Gynecol 108, 428–41 (2006).
5. Harel, Z. Dysmenorrhea in adolescents and young adults: from pathophysiology to pharmacological treatments and management strategies. Expert Opin Pharmacother 9, 2661–72 (2008).
6. Dawood, M. Y. & Khan-Dawood, F. S. Clinical efficacy and differential inhibition of menstrual fluid prostaglandin F2α in a randomized, double-blind, crossover treatment with placebo, acetaminophen, and ibuprofen in primary dysmenorrhea. Am J Obstet Gynecol 196, 35.e1–5 (2007).
7. Ohnishi, M. et al. Role of mitogen-activated protein kinase pathway in prostaglandin F2α-induced rat puerperal uterine contraction. Endocrinology 138, 3103–11 (1997).
8. Marjoribanks, J., Ayeleke, R. O., Farquhar, C. & Proctor, M. Nonsteroidal anti-inflammatory drugs for dysmenorrhea. Cochrane Database Syst Rev 1, CD001751 (2010).
9. Simon, L. S. Nonsteroidal anti-inflammatory drugs and their risk: a story still in development. Arthritis Res Ther 15, Suppl 3:S1 (2013).
10. Zahradnik, H. P., Hanjalic-Beck, A. & Groth, K. Nonsteroidal anti-inflammatory drugs and hormonal contraceptives for pain relief from dysmenorrhea: a review. Contraception 81, 185–96 (2010).
11. Yu, A. Complementary and alternative treatments for primary dysmenorrhea in adolescents. Nurse Pract 39, 1–12 (2014).
12. Palmier, B., Vacher, M., Harbon, S. & Leiber, D. A tyrosine kinase signaling pathway, regulated by calcium entry and dissociated from tyrosine phosphorylation of phosphorylated Cgamma-1, is involved in isositol phosphate production by activated G-protein coupled receptors in myometrium. J Pharmacol Exp Ther 289, 1022–30 (1999).
13. Mills, R. D. et al. A role for the tyrosine kinase FKV2 in depolarization-induced contraction of vascular smooth muscle. J Biol Chem 290, 8677–92 (2015).
14. Phillipe, M., Sweet, L. M., Bradley, D. F. & Engle, D. Role of nonreceptor protein tyrosine kinases during phosphorylation C-gamma 1-related uterine contractions in the rat. Reprod Sci 16, 265–73 (2009).
15. Palmier, B., Leiber, D. & Harbon, S. Pervanadate mediated an increased generation of inositol phosphates and tension in rat myometrium. Activation and phosphorylation of phosphorylase C-gamma-1. Biol Reprod 54, 1383–9 (1996).
16. Goyache, F. M., Gutiérrez, M., Hidalgo, A. & Cantabrana, B. Non-genomic effects of catecholestrogens in the in vitro rat uterine contraction. Gen Pharmacol 26, 219–23 (1995).
17. Cretou, S. M. et al. Complex effects of imatinib on spontaneous and oxytocin-induced contractions in human non-pregnant myometrium. Acta Physiol Hung 98, 329–38 (2011).
18. Hutchings, G., Deprest, J., Nillius, B., Roskams, T. & De Ridder, D. The effect of imatinib mesylate on the contractility of isolated rabbit myometrial strips. Gynecol Obstet Invest 62, 79–83 (2006).
19. Srivastava, A. K. & St-Louis, J. Smooth muscle contractility and protein tyrosine phosphorylation. Mol Cell Biochem 176, 47–51 (1997).
20. Yu, Z. Y. et al. Fluacrypyrim, a novel STAT3 activation inhibitor, induces cell cycle arrest and apoptosis in cancer cells harboring constitutively-active STAT3. Int J Cancer 127, 1259–70 (2010).
21. Gimpl, G. & Fahrenholz, F. The oxytocin receptor system: structure, function, and regulation. Physiol Rev 81, 629–83 (2001).
22. Ito, M., Nakano, T., Erdodi, F. & Hartshorne, D. J. Phosphorylation of smooth muscle myosin at two different sites by myosin light chain kinase. J Biol Chem 260, 10027–31 (1985).
23. De, L., Puerta, R., Martinez, E., Bravo, L. & Ahumada, M. C. Effect of silymarin on different acute inflammation models and on leukocyte migration. J Pharm Pharmacol 48, 968–70 (1996).
24. Sturtevant, W. B. et al. Mitogen-activated protein kinase pathway in prostaglandin F2α-induced rat puerperal uterine contraction. J Pharmacol Exp Ther 326, 207–11 (2001).
25. Xu, Q. et al. Anti-inflammatory and analgesic activity of aqueous extract of Flos populi. J Ethnopharmacol 1192–208 (2009).
26. Szakács, G., Cardenas, E. L., Vásquez, J., Sallés, F. & Bode, U. Isoflavone attenuates vascular contraction through inhibition of the RhoA/Rho-kinase signaling pathway. J Pharmacol Exp Ther 326, 991–8 (2008).
27. Daniels, S., Robbins, J., West, C. R. & Nemeth, M. A. Cecloloxib in the treatment of primary dysmenorrhea: results from two randomized, double-blind, active- and placebo-controlled, crossover studies. Clin Ther 31, 1192–208 (2009).
28. Ohmichi, M. et al. Role of mitogen-activated protein kinase pathway in prostaglandin F2α-induced rat puerperal uterine contraction. J Pharmacol Exp Ther 289, 1022–30 (1999).
29. Okpo, S. O., Fatokun, F. & Adeyemi, O. O. Anti-inflammatory and anti-angiogenic activity of Crinum glaucum aqueous extract. J Ethnopharmacol 185–96 (2010).
30. Yu, H. L., Zhang, F., Li, Y., Gong, G. H. & Quan, Z. S. Anti-inflammatory and antinociceptive effects of 6-(4-chlorophenoxy)-tetrazolo[5,1-a]phthalazine in mice. Pharmacol Rep 64, 1155–65 (2012).
31. De, L., Puerta, R., Martínez, E., Bravo, L. & Ahumada, M. C. Effect of silymarin on different acute inflammation models and on leukocyte migration. J Pharm Pharmacol 48, 968–70 (1996).
32. Inman, D., Frijhoff, J., Sandin, A. & Böhm, F. D. Regulation of protein tyrosine phosphatases by reversible oxidation. J Biochem 150, 345–56 (2011).
33. Frijhoff, J., Dagnell, M., Godfrey, R. & Ostman, A. Regulation of protein tyrosine phosphatase oxidation in cell adhesion and migration. Antioxid Redox Signal 20, 1994–2010 (2014).
34. Brandt, U., Schägger, H. & von Jagow, G. Characterisation of binding of the methoxyacrylate inhibitors to mitochondrial cytochrome c reductase. Eur J Biochem 173, 499–506 (1988).
35. Heine, L. & Dröse, S. Superoxide generation by complex III: from mechanistic rationales to functional consequences. Biochim Biophys Acta 1827, 1320–31 (2013).
36. Skaar, C. E. et al. Mitochondrial and cytoplasmic ROS have opposing effects on lifespan. PLoS Genet 11, e1004972 (2015).
37. Pu, B. C., Fang, L., Gao, L. N., Liu, R. & Li, A. Z. Animal study on primary dysmenorrhea treatment at different administration times. Evid Based Complement Alternat Med 2015, 367379 (2015).
38. Yu, Q. et al. Etoricoxib in the treatment of primary dysmenorrhea in Chinese patients: a randomized controlled trial. Curr Med Res Opin 30, 1863–70 (2014).
39. Guo, L. et al. Active pharmaceutical ingredients and mechanisms underlying phasic myometrial contractions stimulated with the saponin extract from Paris polyphylla Sm. var. yunnanensis used for abnormal uterine bleeding. Hum Reprod 23, 964–71 (2008).

Author Contributions

Y.-W.C. conceived the idea, designed the experiments, wrote and revised the manuscript; Z.-T.L. and L.-M.W. designed and performed the experiments, wrote the manuscript; Y.C. finished the first vision of manuscript; L.G. participated in the experiments; X.-H.L. helped analyze the data; R.-F.Y. supplied the necessary reagents and materials; Z.-Y.Y. and J.-X.D. revised the manuscript; X.-A.W. supervised the whole study and agreed to the final manuscript.
Additional Information

Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Li, Z. et al. Flucrypyrim, a novel uterine relaxant, has antinociceptive and anti-inflammatory effects in vivo. Sci. Rep. 7, 42040; doi: 10.1038/srep42040 (2017).

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

© The Author(s) 2017